Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Cholangiocarcinoma 2Upper Tract Urothelial Carcinomas 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Renal Pelvis and Ureter Urothelial Carcinoma 1Papillomavirus Infections 1Oncogenic osteomalacia 1Nasopharyngeal Neoplasms 1Hypophosphatemia 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Breast Neoplasms 1

Interventions

Temozolomide 22Bevacizumab 10Radiotherapy 5Magnetic Resonance Spectroscopy 5Irinotecan 5Carmustine 4fluorodopa F 18 3Topotecan 3Surgical Procedures, Operative 3Standard of Care 3Radiosurgery 3Magnetic Resonance Imaging 3Congresses as Topic 3Carboplatin 3Aminolevulinic Acid 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3ribociclib 2poly ICLC 2fluoromisonidazole 2carmustine, poliferprosan 20 drug combination 2cabozantinib 2Vorinostat 2TIC10 compound 2Re-Irradiation 2Radiotherapy, Intensity-Modulated 2Panobinostat 2O(6)-benzylguanine 2Melphalan 2Lomustine 2Lacosamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Glioma × infigratinib × Clear all
NCT04424966 2025-10-24

Infigratinib in Recurrent High-Grade Glioma Patients

St. Joseph's Hospital and Medical Center, Phoenix

Phase EARLY_PHASE1 Terminated
7 enrolled 18 charts
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡